3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
2
Paraproteinemias
1
Amyloidosis
1
Alzheimer Disease
1
Interventions
Dexamethasone
2
ixazomib
1
birtamimab
1
Standard of Care
1
Rosiglitazone
1
Neurofeedback
1
Methotrexate
1
Melphalan
1
Mass Screening
1
Magnetic Resonance Imaging
1
Lysine Acetyltransferase 5
1
Hormones
1
Exercise
1
Cyclophosphamide
1
Control Groups
1
Cholinesterase Inhibitors
1
Calcium Dobesilate
1
Bortezomib
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Alzheimer Disease
×
birtamimab
×
Clear all
NCT02632786
2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2
Completed
129 enrolled
18 charts